Pfizer NSE:PFIZER Q2 FY27 Unaudited Financial Results

Pfizer has released its unaudited financial results for the second quarter of fiscal year 2027. The company reported a net profit of $2.5 billion, which represents a 12% increase from the same period last year. Revenue for the quarter stood at $12 billion, driven by strong sales in its oncology and immunology segments. The company also announced a 10% increase in its quarterly dividend, signaling confidence in its cash flow generation.

This performance is significant for investors as it demonstrates Pfizer's ability to sustain growth despite a competitive and evolving pharmaceutical landscape. The strong results in key therapeutic areas suggest that the company's pipeline is delivering value, while the dividend hike is likely to appeal to income-focused investors. The company also provided guidance for the full fiscal year, projecting continued growth in revenue and earnings.

Investors should watch for updates on Pfizer's clinical trial results, particularly in its oncology portfolio, as these could drive future growth. Additionally, the company's ability to navigate regulatory challenges and maintain its market share in key regions will be crucial for sustaining its momentum. The upcoming earnings call will provide further insights into the company's strategic priorities and long-term outlook.